Candid Therapeutics Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 42

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.2B

Candid Therapeutics General Information

Description

Operator of a biotechnology research company designed to create novel, easy-to-administer therapies for autoimmune diseases. The company offers advanced T-cell engager antibodies, precisely redirecting T-cells to selectively eliminate autoreactive B-cells, enabling patients with autoimmune diseases to experience transformative efficacy and improved therapeutic outcomes.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 11622 El Camino Real
  • Suite 150
  • San Diego, CA 92130
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 11622 El Camino Real
  • Suite 150
  • San Diego, CA 92130
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Candid Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 01-Mar-2026 $2.2B Completed Clinical Trials - Phase 1
5. PIPE 09-Mar-2026 Cancelled Clinical Trials - Phase 1
4. Reverse Merger 02-Mar-2026 Cancelled Clinical Trials - Phase 1
3. Early Stage VC (Series B) 20-Aug-2024 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A) 18-Jul-2024 $164M $164M Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Clinical Trials - Phase 1
To view Candid Therapeutics’s complete valuation and funding history, request access »

Candid Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-2
Series A-1 105,000,000 $0.000100 8% $1 $1 1x $1 18.33%
To view Candid Therapeutics’s complete cap table history, request access »

Candid Therapeutics Patents

Candid Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026165008-A1 Compositions and methods of use of multispecific antibodies Pending 29-Jan-2025
WO-2026161569-A2 Compositions and methods of use of multispecific antibodies Pending 24-Jan-2025
WO-2026161569-A3 Compositions and methods of use of multispecific antibodies Pending 24-Jan-2025
WO-2026161360-A1 Compositions of multispecific antibodies and methods of use thereof Pending 21-Jan-2025
WO-2026136426-A1 Compositions and methods of use of antibodies targeting cd20 and cd3 Pending 18-Dec-2024 A61P37/06
To view Candid Therapeutics’s complete patent history, request access »

Candid Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Candid Therapeutics Former Investors (28)

Investor Name Investor Type Holding Investor Since Participating Rounds
Boxer Capital Corporate Venture Capital Minority
Cormorant Asset Management PE/Buyout Minority
Fairmount Partners Investment Bank Minority
Fidelity Management & Research Company Asset Manager Minority
Foresite Capital Growth/Expansion Minority
You’re viewing 5 of 28 investors. Get the full list »

Candid Therapeutics Investments & Acquisitions (3)

Candid Therapeutics’s most recent deal was a Corporate Asset Purchase with WuXi Biologics (Preclinical Trispecific T-cell Engager in Wuxi, China). The deal was made on 06-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
WuXi Biologics (Preclinical Trispecific T-cell Engager in Wuxi, China) 06-Jan-2025 Corporate Asset Purchase Buildings and Property
TRC 2004 09-Sep-2024 Merger/Acquisition Drug Discovery
Vignette Bio 19-Aug-2024 Merger/Acquisition Drug Discovery
To view Candid Therapeutics’s complete investments and acquisitions history, request access »

Candid Therapeutics Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Vignette Bio San Diego, CA 2023
TRC 2004 San Diego, CA 2020

Candid Therapeutics FAQs

  • When was Candid Therapeutics founded?

    Candid Therapeutics was founded in 2024.

  • Where is Candid Therapeutics headquartered?

    Candid Therapeutics is headquartered in San Diego, CA.

  • What is the size of Candid Therapeutics?

    Candid Therapeutics has 42 total employees.

  • What industry is Candid Therapeutics in?

    Candid Therapeutics’s primary industry is Drug Discovery.

  • Is Candid Therapeutics a private or public company?

    Candid Therapeutics is a Private company.

  • What is the current valuation of Candid Therapeutics?

    The current valuation of Candid Therapeutics is .

  • What is Candid Therapeutics’s current revenue?

    The current revenue for Candid Therapeutics is .

  • How much funding has Candid Therapeutics raised over time?

    Candid Therapeutics has raised $370M.

  • Who are Candid Therapeutics’s investors?

    Boxer Capital, Cormorant Asset Management, Fairmount Partners, Fidelity Management & Research Company, and Foresite Capital are 5 of 28 investors who have invested in Candid Therapeutics.

  • When was Candid Therapeutics acquired?

    Candid Therapeutics was acquired on 01-Mar-2026.

  • Who acquired Candid Therapeutics?

    Candid Therapeutics was acquired by UCB.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process